Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 2/20 | 0.40 |
| ▸ | VCP | P55072 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29833734 | 0.84 | S100A4 (0.45) | S100A4GPR35GRIN2DGRIN3BGRIN1 | |
| SCHEMBL103726 | 0.84 | S100A4 (0.45) | S100A4GPR35GRIN2DGRIN3BGRIN1 | |
| SCHEMBL16739101 | 0.80 | VCP (0.40) | VCPALDH1A1HIF1AVCAM1ATM | |
| SCHEMBL29686335 | 0.80 | VCP (0.40) | VCPALDH1A1HIF1AVCAM1ATM | |
| SCHEMBL5780946 | 0.77 | ALDH1A1 (0.45) | S100A4GPR35GRIN2DGRIN3BGRIN1 | |
| SCHEMBL21487236 | 0.77 | TSHR (0.41) | S100A4GPR35GRIN2DGRIN3BGRIN1 | |
| SCHEMBL16037644 | 0.77 | GPR35 (0.42) | S100A4VCPGPR35GRIN2DGRIN3B | |
| SCHEMBL21487115 | 0.77 | ALDH1A1 (0.50) | S100A4GPR35GRIN2DGRIN3BGRIN1 | |
| SCHEMBL6382937 | 0.77 | GPR35 (0.40) | S100A4VCPGPR35GRIN2DGRIN3B | |
| SCHEMBL102206 | 0.77 | TSHR (0.45) | S100A4GPR35GRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637435-B2 | Nitrogen-containing heterocyclic compound or salt thereof, use thereof, and intermediate thereof | FUJIFILM CORPORATION (JP) | 2026-05-26 | — | — | US | disclosed |
| US-12577258-B2 | Macrocyclic compound | VERNALIS (R&D) LIMITED (GB) | 2026-03-17 | — | — | US | disclosed |
| EP-4667461-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON S AND GAUCHER DISEASE | Children's Hospital Medical Center (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250382274-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S AND GAUCHER DISEASE | CHILDRENS HOSPITAL MED CT (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4190402-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF | FUJIFILM CORP (JP) | 2025-08-27 | — | — | EP | disclosed |
| US-20250163004-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2025-05-22 | — | — | US | disclosed |
| EP-4223368-B1 | MACROCYCLIC COMPOUNDS INCORPORATING PIPERIDINE AND QUINOLINE OR QUNAXOLINE AS IRAK-4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS | ASAHI KASEI PHARMA CORP (JP) | 2025-05-21 | — | — | EP | disclosed |
| US-20250115606-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2025-04-10 | — | — | US | disclosed |
| EP-4524139-A1 | IMIDAZOPYRIDAZINE SUBSTITUTED BENZENE RING DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2025-03-19 | — | — | EP | disclosed |
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20130178631-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2013-07-11 | — | — | US | disclosed |
| CN-102993084-A | Alkynyl derivatives as modulators of metabotropic glutamate receptors | ADDEX PHARMACEUTICALS SA | 2013-03-27 | — | — | CN | disclosed |
| CN-101001846-B | Alkynyl derivatives as modulators of metabotropic glutamate receptors | ADDEX PHARMACEUTICALS SA | 2012-11-07 | — | — | CN | disclosed |
| US-20120277237-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2012-11-01 | — | — | US | disclosed |
| EP-2426115-A2 | Alkynyl derivatives as modulators of metabotropic glutamate receptors | Addex Pharma SA (CH) | 2012-03-07 | — | — | EP | disclosed |
| US-8101637-B2 | Alkynyl derivatives as modulators of metatropic glutamate receptors | ADDEX PHARMA SA (CH) | 2012-01-24 | — | — | US | disclosed |
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2009-05-14 | — | — | US | disclosed |
| CN-101001846-A | Novel alkynyl derivatives as modulators of metabotropic glutamate receptors | ADDEX PHARMACEUTICALS SA (CH) | 2007-07-18 | — | — | CN | disclosed |
| EP-1765795-A2 | ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharmaceuticals SA (CH) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123703-A2 | ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178631-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | S100A4 3878/4885VCP 2515/4885GPR35 36/4885 |
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | S100A4 3700/4885VCP 3185/4885GPR35 37/4885 |
| US-12577258-B2 | Macrocyclic compound | IRAK1, IRAK4, IRAK2 | S100A4 4053/4885VCP 4455/4885GPR35 2402/4885 |
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, DYRK2, DYRK1A | S100A4 4420/4885VCP 3387/4885GPR35 3422/4885 |
| US-20250115606-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | S100A4 3270/4885VCP 2893/4885GPR35 69/4885 |
| US-20120277237-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | S100A4 3878/4885VCP 2515/4885GPR35 36/4885 |
| US-20250163004-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | TYK2, JAK2, STAT3 | S100A4 3673/4885VCP 4663/4885GPR35 994/4885 |
| US-20250382274-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S AND GAUCHER DISEASE | GBA1, GAA, GBA2 | S100A4 4620/4885VCP 626/4885GPR35 2072/4885 |
| US-12637435-B2 | Nitrogen-containing heterocyclic compound or salt thereof, use thereof, and intermediate thereof | CBR1, DHODH, CBR3 | S100A4 3990/4885VCP 3939/4885GPR35 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.